Ignite Creation Date:
2024-06-16 @ 11:52 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06453460
Status:
RECRUITING
Last Update Posted:
2024-07-15
First Post:
2024-06-05
Brief Title:
Prospect Eval of Efficacy of CMV-TCIP Direct Letermovir Prophylax After Allogen Hemato Cell Transpla
Sponsor:
University of California Irvine
Organization:
University of California Irvine
Study Overview
Official Title:
Prospective Evaluation of Efficacy of CMV-specific T Cell Immunity CMV-TCIP Directed Letermovir Prophylaxis After Allogeneic Hematopoietic Cell Transplantation
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a phase 2 prospective cohort clinical trial evaluating the utilization of CMV T Cell Immunity Panel CMV-TCIP assay to guide the duration of primary CMV prophylaxis in CMV-seropositive recipients of allogeneic stem cell transplant or recipients receiving a stem cell graft from a CMV serology positive donor
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
True
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| UCI 22-188 | OTHER | UCI | None |